Lupin’s Nagpur Facility Receives EIR From The U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Nagpur facility. The facility was inspected by the U.S. FDA between August 5, 2019 and August 8, 2019.

The inspection for the oral solid facility at Nagpur closed without any Form 483 observation. The Nagpur facility is Lupin’s largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance.

Commenting on the receipt of the EIR, Nilesh Gupta, Managing Director, Lupin said, “Excelling at Quality and Compliance is one of our top priorities and we remain committed to meeting and exceeding standards set by regulatory agencies globally.”

Shares of LUPIN LTD. was last trading in BSE at Rs.726.4 as compared to the previous close of Rs. 732.3. The total number of shares traded during the day was 24072 in over 728 trades.

The stock hit an intraday high of Rs. 732 and intraday low of 719.35. The net turnover during the day was Rs. 17437490. – Equity Bulls